CUE
Cue Biopharma, Inc.
Next earnings Aug 10, 2026 · consensus $-1.71 EPS, $3.03M rev
$25.39
▼ -0.59%$25.39▲ +29.21%
over 1Y
L $5.31EODHDH $35.73
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.6%
1W-17.4%
1M+24.2%
3M+253.5%
YTD+150.8%
1Y+29.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 5 analysts
Buy
Revenue grew 195.7% YoY; but unprofitable (net margin -96.9%).
Revenue (FY2025) $27.5M · FY2025
Cue Biopharma, Inc. shows $27.5M in FY2025 revenue (+195.7% YoY), a -96.9% net margin, and -100.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $14.9M | $1.25M | $5.49M | $9.29M | $27.5M |
| Gross profit | — | — | — | — | — |
| Operating income | -$43.7M | -$53.2M | -$52.1M | -$41.5M | -$26.6M |
| Net income | -$44.2M | -$53.0M | -$50.7M | -$40.7M | -$26.6M |
| Diluted EPS | -$1.41 | -$1.49 | -$1.11 | -$0.72 | -$0.28 |
| Net margin | -295.6% | -4257.8% | -924.1% | -438.0% | -96.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.45B
EV / EBITDA—
EV / Sales89.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-1.1%
FCF yield-0.9%
Quality & risk
ROIC (est.)-79.2%
Free cash flow-$21.9M
Total debt$37.0K
Net cash$27.1M
Altman Z-Score81.30 safe
Piotroski F-Score5/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+58.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- S-3 Shelf registration (potential raise)2026-06-18
- 8-K Officer / director change2026-06-03
- S-3 Shelf registration (potential raise)2026-06-03
- 8-K Officer / director change2026-06-02
- DEF 14A Proxy statement2026-05-21
- 8-K Exhibits2026-05-14
- 10-Q Quarterly report2026-05-14
- 8-K Officer / director change2026-05-01
- 8-K Material event2026-04-22
Recent filings
all on EDGAR ↗S-3Filing2026-06-18open ↗EFFECTFiling2026-06-17open ↗3Period ending 2026-06-012026-06-11open ↗3Period ending 2026-06-012026-06-11open ↗4Period ending 2026-05-302026-06-08open ↗3Period ending 2026-05-302026-06-08open ↗4Period ending 2026-06-012026-06-03open ↗8-KPeriod ending 2026-06-012026-06-03open ↗S-8Filing2026-06-03open ↗S-3Filing2026-06-03open ↗4Period ending 2026-05-302026-06-02open ↗3Period ending 2026-05-302026-06-02open ↗
Frequently asked
- Is Cue Biopharma, Inc. (CUE) a buy?
- CUE currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 195.7% YoY; but unprofitable (net margin -96.9%).
- What is Cue Biopharma, Inc.'s quality score?
- CUE scores 48.56862745098039/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001645460, latest 10-Q filed 2026-05-14) · EODHD · as of 6/22/2026, 11:38:18 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.